Award

CO-US-412-3992

Funder: Gilead Sciences

Funded outputs count: 2

Funder award ID: CO-US-412-3992

OpenAlex ID: G316797988

An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics

2026 · Peter L. Anderson, Alina PS Pang, et al. · medRxiv · 4

Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV

2025 · Vincent A Mainella, Brian Branchford, et al. · Journal of Antimicrobial Chemotherapy · 1